The Europe and Middle East & Africa respiratory panel testing market is projected to experience steady expansion as healthcare providers increasingly adopt rapid, automated, and comprehensive diagnostic technologies for respiratory infections. According to Transparency Market Research, the market was valued at more than US$1.6 Bn in 2020 and is estimated to expand at a CAGR of 5.1% from 2021 to 2031, surpassing US$3.1 Bn by the end of 2031.

Respiratory panel testing enables healthcare professionals to identify multiple viral and bacterial pathogens from a single specimen. The technology has become increasingly important as respiratory diseases often present with similar symptoms, making it difficult to distinguish between different pathogens based solely on clinical assessment. Comprehensive panels can provide clinicians with information that supports decisions concerning treatment, patient isolation, admission, and additional diagnostic procedures.

Rising Burden of Respiratory Infections Supports Market Expansion

The increasing prevalence of respiratory tract infections is one of the primary factors driving demand for respiratory panel testing across Europe, the Middle East, and Africa. Respiratory illnesses range from self-limiting upper respiratory tract infections to more serious conditions such as bronchitis and pneumonitis.

Lower respiratory tract infections can be particularly serious among infants, older adults, and vulnerable patient groups. Growing hospitalization rates associated with respiratory diseases are increasing the need for diagnostic tools that can provide accurate results quickly. Respiratory panel testing offers an approach for simultaneously evaluating multiple potential pathogens, helping healthcare providers obtain broader diagnostic information from a single sample.

The continuing prevalence of seasonal influenza, respiratory syncytial virus (RSV), rhinovirus, adenovirus, human metapneumovirus, parainfluenza, and other respiratory pathogens is expected to sustain demand for testing solutions.

Multiplex PCR Emerges as a Key Technology

Technological development in molecular diagnostics is transforming respiratory pathogen detection. Multiplex polymerase chain reaction (PCR) panels can simultaneously identify multiple target DNA or RNA molecules within a single reaction. This makes multiplex testing particularly valuable when several pathogens can produce similar clinical symptoms.

PCR-based respiratory panels are increasingly viewed as an alternative to conventional viral culture, which can be comparatively slow and labor-intensive. Molecular panels can provide faster results with high sensitivity and specificity, enabling clinicians to make more timely decisions.

Manufacturers are consequently expanding their portfolios of multiplex respiratory panels targeting pathogens such as influenza, RSV, rhinovirus, coronavirus, SARS-CoV-2, and other viral and bacterial agents. The growing availability of automated systems that minimize manual pipetting and sample preparation is also supporting adoption.

Syndromic Full Multiplex Panels Maintain Strong Market Potential

By panel type, the market is segmented into syndromic full multiplex panels and low-plex panels. Syndromic full multiplex panels accounted for the largest market share in 2020, according to the market analysis.

These systems are designed to detect multiple pathogens associated with a particular clinical syndrome within a single PCR reaction. Their ability to provide broad diagnostic information can be valuable in clinical settings where symptoms alone cannot reliably distinguish among viral and bacterial infections.

Syndromic molecular testing is increasingly being incorporated into routine clinical workflows to support diagnostic, epidemiological, and patient-management decisions. Continued improvements in assay performance, automation, and turnaround time are expected to create further opportunities for this segment during the forecast period.

Demand for Rapid and Comprehensive Testing Creates Opportunities

Healthcare providers are increasingly seeking respiratory panels that combine broad pathogen coverage with short turnaround times. Fast results can be particularly valuable in emergency departments, intensive-care settings, hospital laboratories, and point-of-care environments.

The market outlook indicates an opportunity for manufacturers to develop panels capable of delivering comprehensive results in less than an hour. Such systems could help clinicians make faster decisions related to admission, isolation, additional diagnostic testing, and patient management.

High sensitivity and specificity are also critical purchasing considerations. Regulatory and quality credentials, including CE-marked and other authorized diagnostic products, can strengthen confidence among healthcare providers and support wider adoption.

Home Testing and Nasopharyngeal Sampling Expand Accessibility

The growing emphasis on convenient diagnostic testing is opening additional opportunities for respiratory panel testing. Nasopharyngeal swabs remain an important specimen collection method for respiratory pathogen detection, while laboratories and healthcare providers are also exploring home-testing models and eCommerce-enabled distribution.

The expansion of home testing can improve convenience for individuals while reducing the need for some patients to travel to healthcare facilities for diagnostic procedures. Demand for testing human rhinovirus, human metapneumovirus, adenovirus, parainfluenza, and other respiratory pathogens is contributing to opportunities for manufacturers developing convenient collection and testing solutions.

Europe Leads the EMEA Respiratory Panel Testing Market

Europe represented 85.5% of the EMEA respiratory panel testing market in 2020, making it the dominant regional market. Factors supporting European demand include the prevalence of respiratory diseases, an aging population, technological advancements in molecular diagnostics, and established healthcare and laboratory infrastructure.

Germany is expected to remain a leading market within Europe due to its established medical diagnostics industry and healthcare infrastructure. The U.K., France, Italy, Spain, Switzerland, the Benelux region, Poland, and Nordic countries also represent important markets for respiratory testing technologies.

Meanwhile, the Middle East and Africa are expected to offer opportunities as healthcare infrastructure develops and demand for advanced diagnostic technologies increases. Investments in laboratories, point-of-care testing, and infectious-disease management can support long-term market development across the region.

Hospitals and Reference Laboratories Drive Adoption

By end-user, the market includes hospital point-of-care testing, reference laboratories, hospitals, and others. Hospitals are expected to remain important users of respiratory panel testing as rising respiratory disease incidence contributes to patient admissions.

Reference laboratories also represent a significant opportunity because of their role in processing diagnostic samples and supporting healthcare institutions. Point-of-care testing can provide another avenue for expansion, particularly where rapid diagnostic information is essential for immediate clinical decision-making.

Competitive Landscape Focuses on Innovation

The competitive landscape includes major diagnostic and healthcare technology companies such as F. Hoffmann-La Roche Ltd., bioMérieux SA, Medline Industries, Becton, Dickinson & Company, altona Diagnostics GmbH, CerTest Biotec S.L., Anatolia Geneworks, Seegene, DiaSorin/Luminex, QIAGEN, and Biocartis.

Market participants are focusing on product launches, regulatory approvals, expanded specimen options, automation, and strategic collaborations to strengthen their positions. Developments cited in the market analysis include DiaSorin's CE Mark expansion for saliva specimens with its Simplexa COVID-19 Direct assay, altona Diagnostics' launch of the RealStar SARS-CoV-2 RT-PCR Kit 1.0, and Anatolia Geneworks' respiratory pathogen panel launch.

Market Outlook

The Europe and Middle East & Africa respiratory panel testing market is expected to maintain positive momentum through 2031 as healthcare systems prioritize early and accurate detection of respiratory pathogens. Multiplex PCR, syndromic testing, automation, point-of-care diagnostics, and convenient specimen collection are expected to remain important areas of innovation.

With the market projected to grow from more than US$1.6 Bn in 2020 to over US$3.1 Bn by 2031, manufacturers that can deliver rapid, comprehensive, sensitive, and user-friendly respiratory testing solutions are positioned to benefit from emerging opportunities.

The combination of respiratory disease prevalence, technological advances, demand for rapid diagnosis, and continued investment in healthcare diagnostics is expected to reinforce the strategic importance of respiratory panel testing across Europe and the Middle East & Africa. As clinical laboratories and healthcare providers increasingly seek efficient methods for identifying multiple pathogens from a single specimen, respiratory panel testing is likely to remain an important component of modern infectious-disease diagnostics through the forecast period.